Fresh off $67M financing, Alentis thinks direct anti-fibrotic approach could fill industry gap

Alentis Therapeutics needs to deliver the primary anti-fibrotic remedy to handle underlying liver and kidney illnesses into the clinic, and a brand new money infusion of $67 million will assist.  French personal fairness agency Jeito Capital and Chinese enterprise agency...